Ahead of clos­ing $11.5B Ac­celeron buy­out, Mer­ck is on the hunt for more deals

Some­where in Ke­nil­worth, NJ, Mer­ck’s CEO Robert Davis is do­ing the hap­py dance. If all goes ac­cord­ing to plan, he’ll close out this year with the com­pa­ny’s $11.5 bil­lion Ac­celeron buy­out in the books, plus an ex­pect­ed $5 to $7 bil­lion wind­fall from its an­tivi­ral Covid-19 pill. But why stop there?

On the phar­ma gi­ant’s Q3 earn­ings call, the chief ex­ec­u­tive con­firmed that more M&A deals — and big ones, at that — are com­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER